Search / Trial NCT00001741

Study of Inherited Changes of Receptors Located on Blood Vessels

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Trial Information

Current as of November 14, 2024

Completed

Keywords

Angiotensin Ii Receptor Polymorphism, Genetic Vascular Tone Angiotensin Ii Losartan

ClinConnect Summary

Polymorphisms in the genes encoding for various elements of the renin angiotensin system have been associated with cardiovascular disease. We have isolated novel alleles in the angiotensin II type I receptor gene. We propose this exploratory investigation to study the physiological effect of these mutations on vascular function in patients and family members who carry these rare alleles.

Gender

ALL

Eligibility criteria

  • Patients aged 21 or older with chronic orthostatic intolerance will be included.
  • There will be no exclusion from participation in the study on the basis of ethnicity/race.
  • Patients will be recruited in the Cardiology Branch outpatient clinic, Dr. David Goldstein (Chief Neurocardiology Section, NINDS, NIH), or from outside physicians.
  • Children will be excluded from the study because of inability in obtaining informed consent.
  • Cognitively impaired individuals, prisoners, or other institutionalized persons will not be able to participate.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials